Sbir phase I-radionuclide therapy for metastatic melanoma viewpoint molecular targeting, LLC:1256544 [15-068338]
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201500069C
- Awardee
-
Viewpoint Molecular Targeting, Inc. UEI RDZCK3F6AU73
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $298,184
Award facts
- Opportunity
-
- PHS20151 Solicitation number
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Award Notice · Posted Jul 31, 2014
- Contract value 100% obligated
- $298,184.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- R699 Support- Administrative: Other
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 11 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Iowa City, IA 52246, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $298,184 |
About this award
This is a $298,184 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Viewpoint Molecular Targeting, Inc. for a Small Business Innovation Research (SBIR) Phase I project related to radionuclide therapy for metastatic melanoma. The contract has a total small business set-aside and is focused on preclinical research and development, including pharmacology, toxicology, biodistribution, and dosimetry studies, cGMP manufacturing, and clinical trial preparation for a lead-212 based targeted alpha particle therapy. Viewpoint Molecular Targeting has received over $15 million in prior federal grants from NCI to advance the development of its lead-212 cancer therapies, including work on combining the targeted alpha particle therapy with immunotherapy.
Quick answers
Who was awarded contract HHSN261201500069C?
HHSN261201500069C was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2015.
How much is contract HHSN261201500069C worth?
The government has obligated $298,184 on HHSN261201500069C.
Was contract HHSN261201500069C competed?
The extent of competition for HHSN261201500069C was full and open competition after exclusion of sources. The government received 11 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award